NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Pediatric Prospective Personalized Immune and Target Identification Trial

CompletedNA

Sponsor: Masaryk University

Conditions: Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain

Interventions: FoundationOneHeme

Countries: Austria, Czechia

PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.

Eligibility overview

Sex: ALL

Age: 1 Year to 19 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Patient Informed consent form must be appropriately obtained under the applicable local and regulatory requirements. Each patient must sign a consent form prior the enrollment to document their willingness to participate.
2. The subject is male or female, aged 1 - 19 years
3. The subject must have a histologically proven recurrent/ refractory or very high-risk CNS tumors
4. Patients must be in good overall physical condition, which allows tumor biopsy
5. Patients must have a life expectancy of at least 3 months.
6. Patients must have a tumor amenable to image-guided or direct vision biopsy and be willing and able to undergo a tumor biopsy and/or blood taking for molecular profiling.
7. Patients must be accessible for follow-up.

Exclusion Criteria:

1. Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
2. Pregnant and/or breastfeeding women, if applicable
3. No intention to treat the patient.

Locations (3)

Vienna, Spitalgasse 23,, Austria
Prague, V Úvalu 84,, Czechia
Brno, Černopolní 9,, Czechia